IQ EQ FUND MANAGEMENT IRELAND Ltd Has $954,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

IQ EQ FUND MANAGEMENT IRELAND Ltd lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 15.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,857 shares of the medical research company’s stock after selling 862 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in IQVIA were worth $954,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the 4th quarter valued at about $33,000. Lee Danner & Bass Inc. bought a new position in IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. lifted its stake in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Versant Capital Management Inc grew its position in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of IQVIA during the 4th quarter worth $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the subject of a number of recent research reports. Bank of America decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Citigroup dropped their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. UBS Group lowered their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Down 0.3 %

Shares of IQVIA stock opened at $179.40 on Friday. IQVIA Holdings Inc. has a 1 year low of $176.74 and a 1 year high of $253.84. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market capitalization of $31.63 billion, a P/E ratio of 23.92, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business has a 50-day moving average of $193.55 and a two-hundred day moving average of $206.91.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.